Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Principal Financial Group Inc. lifted its stake in shares of Biogen by 3.2% during the third quarter. Principal Financial ...
Biogen (BIIB) Company Description: Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of ...
We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...
On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...
(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Venturi Wealth Management LLC raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 73.8% in the 3rd quarter, ...
The company's CEO warned on Wednesday that U.S. revenue for Leqembi, which it developed in partnership with Eisai Inc., “continues to be below the expectations of our collaboration.” ...
INCHEON, South Korea and CAMBRIDGE, MA, USA I November 18, 2024 I Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback